Table 1 Subject characteristics
From: Characterization of HIV-1 envelopes in acutely and chronically infected injection drug users
Subject | Estimated PI (months) 1 | Plasma virus level | CCR5 2 | CXCR4 3 | Tropism 4 |
|---|---|---|---|---|---|
A31 | Ab-/ VL+ | 154, 381 | 12.7 | 13.83 | R5/X4 |
A33 | Ab-/ VL+ | 1, 031, 929 | 9.7 | <0.03 | R5 |
A38 | Ab-/ VL+ | 31, 174 | 10.8 | <0.03 | R5 |
A40 | Ab-/ VL+ | 14, 422 | 14.9 | <0.03 | R5 |
A41 | Ab-/ VL+ | 1, 289,549 | 13.3 | <0.03 | R5 |
A42 | Ab-/ VL+ | 2, 285, 517 | 12.6 | <0.03 | R5 |
A43 | Ab-/ VL+ | 499, 713 | 12.3 | <0.03 | R5 |
A2 | 3.0 | 85, 439 | 11.5 | <0.03 | R5 |
A4 | 5.0 | 2, 158, 680 | 1.9 | 14.3 | R5/X4 |
A5 | 4.1 | 279, 745 | 8.7 | <0.03 | R5 |
A17 | 4.9 | 40, 634 | 14.6 | <0.03 | R5 |
A18 | 3.2 | 188, 258 | 12.1 | <0.03 | R5 |
A23 | 4.9 | 56, 189 | 10.6 | <0.03 | R5 |
A27 | 4.1 | 152, 472 | 10.4 | <0.03 | R5 |
A2 | 21.4 | 30, 996 | 19.1 | <0.03 | R5 |
A4 | 24.5 | 79, 094 | 0.3 | 12.2 | R5/X4 |
A5 | 27.2 | 137, 661 | 11.1 | <0.03 | R5 |
A17 | 20.9 | 20, 995 | 13.0 | <0.03 | R5 |
A18 | 27 | 12, 299 | 11.6 | <0.03 | R5 |
A23 | 27.7 | 79, 490 | 12.1 | <0.03 | R5 |
A27 | 27.1 | 17, 668 | 9.8 | 11.91 | R5/X4 |